Clinical Trial Update: Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag [NA]

View source ↗

Summary

This clinical trial update describes a study to prevent thrombocytopenia in HER2-positive breast cancer patients treated with ado-trastuzumab emtansine (T-DM1) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Herombopag (herombopag)
• T-DM1 (ado-trastuzumab emtansine)

Snippet

Sponsor: Zhenzhen Liu | Conditions: HER2-positive Breast Cancer | NA | Status: NOT_YET_RECRUITING